继发性甲状旁腺功能亢进消融治疗进展  

Progress of ablation for secondary hyperparathyroidism

作　　者：刁宗礼[1] 王丽妍[1] 代文迪[1] 刘文虎[1] 

机构地区：[1]首都医科大学附属北京友谊医院肾内科,100050

出　　处：《中华全科医师杂志》2016年第4期318-320,共3页Chinese Journal of General Practitioners

基　　金：国家自然科学基金（81300607）;北京市科技计划课题项目（D131100004713001）

摘　　要：继发性甲状旁腺功能亢进（SHPT）是透析患者的常见并发症，与患者生活质量、心血管事件和死亡密切相关。活性维生素D及其类似物是SHPT的主要治疗药物，但对重度SHPT患者往往无效，或因血钙磷水平控制欠佳难以给予药物治疗。对此类患者可给予手术或消融治疗。消融治疗作为一种微创手术，越来越多地应用于临床治疗SHPT，取得了许多新的进展。Secondary hyperparathyroidism （SHPT） is the common complication in chronic kidney disease patients, especially in those with hemodialysis, which is associated with cardiovascular events and mortality. Active vitamin D and its analogues are classic treatment for SHPT, but some patients are resistant to active vitamin D, and ablation would be a choice for such cases. The purpose of this review is to provide current progress in ablation for SHPT.

关 键 词：甲状旁腺功能亢进症 继发性 消融技术 

分 类 号：R582.1[医药卫生—内分泌]